Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK.


Journal

Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320

Informations de publication

Date de publication:
16 01 2019
Historique:
received: 16 04 2018
revised: 03 10 2018
accepted: 20 11 2018
pubmed: 24 12 2018
medline: 14 8 2019
entrez: 22 12 2018
Statut: ppublish

Résumé

It is often unclear why some genetic mutations to a given gene contribute to neurological disorders and others do not. For instance, two mutations have previously been found to produce a dominant negative for TRESK, a two-pore-domain K+ channel implicated in migraine: TRESK-MT, a 2-bp frameshift mutation, and TRESK-C110R. Both mutants inhibit TRESK, but only TRESK-MT increases sensory neuron excitability and is linked to migraine. Here, we identify a new mechanism, termed frameshift mutation-induced alternative translation initiation (fsATI), that may explain why only TRESK-MT is associated with migraine. fsATI leads to the production of a second protein fragment, TRESK-MT2, which co-assembles with and inhibits TREK1 and TREK2, two other two-pore-domain K+ channels, to increase trigeminal sensory neuron excitability, leading to a migraine-like phenotype in rodents. These findings identify TREK1 and TREK2 as potential molecular targets in migraine and suggest that fsATI should be considered as a distinct class of mutations.

Identifiants

pubmed: 30573346
pii: S0896-6273(18)31048-1
doi: 10.1016/j.neuron.2018.11.039
pii:
doi:

Substances chimiques

Kcnk10 protein, mouse 0
Kcnk18 protein, rat 0
Neurotransmitter Agents 0
Potassium Channels 0
Potassium Channels, Tandem Pore Domain 0
potassium channel protein TREK-1 0
Nitric Oxide 31C4KY9ESH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

232-245.e6

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Perrine Royal (P)

Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France.

Alba Andres-Bilbe (A)

Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Pablo Ávalos Prado (P)

Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France.

Clément Verkest (C)

Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.

Brigitte Wdziekonski (B)

Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France.

Sébastien Schaub (S)

Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France.

Anne Baron (A)

Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Florian Lesage (F)

Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France; Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.

Xavier Gasull (X)

Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.

Joshua Levitz (J)

Department of Biochemistry, Weill Cornell Medicine, New York, NY, USA.

Guillaume Sandoz (G)

Université Côte d'Azur, CNRS, Inserm, Institut de Biologie Valrose, Nice, France; Laboratories of Excellence, Ion Channel Science and Therapeutics, Nice, France. Electronic address: sandoz@unice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH